Melanotan 2 Protocol: Complete Cycling & Dosing Guide

Melanotan 2 Protocol: Complete Cycling & Dosing Guide

Overview

Melanotan II (MT-II) is a synthetic melanocortin receptor agonist originally developed for photoprotection and tanning. It functions as a non-selective agonist at MC1R, MC3R, MC4R, and MC5R receptors, producing effects ranging from skin pigmentation to appetite suppression, energy expenditure changes, and sexual function enhancement.

Critical Safety Note: MT-II is not FDA or EMA approved and carries unresolved safety concerns, particularly regarding melanoma risk and dysplastic nevi proliferation. This guide is educational content only and does not constitute medical advice. Consult a dermatologist before use, especially if you have a personal or family history of melanoma or atypical moles.

Standard Protocol: Loading & Maintenance Phase

The conventional MT-II protocol employs a loading phase followed by maintenance dosing.

Loading Phase (7–14 days)

• Dose: 0.25–0.5 mg injected once daily
• Duration: Continue until desired tan depth is achieved or side effects become intolerable
• Typical timeframe: 7–14 days for noticeable pigmentation
• Route: Subcutaneous injection (preferred) or nasal (less common)

Maintenance Phase (ongoing)

• Dose: 0.25–0.5 mg injected 2–3× per week
• Frequency: Every 2–3 days
• Duration: As long as desired tanning effect is maintained
• Adjustment: Many users reduce to 0.1–0.2 mg for maintenance once pigmentation is locked in

Nasal Route Alternative

• Dose: 0.5–1 mg per spray, once daily
• Frequency: Single daily application
• Absorption: Slower and less predictable than injection; requires more frequent dosing for equivalent effect

Goal-Specific Protocols

Protocol A: Tanning & Photoprotection (Primary Indication)

Duration: 14–21 days loading, then 8–12 week maintenance blocks

Dermatological Monitoring: Baseline full-body skin exam before starting. Monthly mole mapping during maintenance. Discontinue immediately if new atypical lesions appear or existing moles change.

Protocol B: Energy & Fat Loss (Appetite Suppression Focus)

Duration: 12–16 week cycle with built-in rest periods

Weeks 1–4 (Loading)

• Dose: 0.25–0.5 mg daily (subcutaneous)
• Timing: Inject in evening to manage nausea
• Expect: Appetite suppression onset by day 3–5; peak effect by week 2

Weeks 5–12 (Maintenance)

• Dose: 0.25 mg 3× weekly (Monday, Wednesday, Friday)
• Timing: Inject 2–3 hours before largest meal
• Dietary synergy: Reduced caloric intake is natural; do not force additional restriction

Weeks 13–16 (Deload/Taper)

• Dose: 0.125 mg 2× weekly, then 0 (cease entirely)
• Tapering prevents rebound hunger surge
• Resume normal eating patterns over 5–7 days

Expected outcome: 8–15 lb fat loss alongside appetite suppression; no clinical human data on efficacy, but consistent animal evidence supports appetite reduction.

Protocol C: Sexual Function & Libido (ED/Desire Enhancement)

Duration: 8–12 week responsive cycle

Weeks 1–2 (Loading)

• Dose: 0.25 mg once daily (evening preferred)
• Timing: Inject 30–90 minutes before intended sexual activity
• Expected onset: Erections possible within 15–45 minutes; sustained effect 1–4 hours

Weeks 3–8 (Maintenance)

• Dose: 0.25 mg 2–3× weekly (or as-needed)
• PRN dosing: Inject 30–60 minutes before sexual activity
• Benefit: Reduced systemic exposure if using sporadically

Discontinuation Protocol

• No taper necessary for sexual function dosing
• Stop entirely after 8–12 weeks; reassess in 4 weeks
• Higher doses (0.5+ mg) carry priapism risk—avoid

Priapism Warning: Erections lasting >4 hours require immediate medical attention. Keep phenylephrine or dilute epinephrine available if using >0.3 mg doses.

How to Administer: Step-by-Step

Subcutaneous Injection (Preferred Route)

Reconstitution (if powder)

1. Obtain bacteriostatic water (0.9% sodium chloride + 0.9% benzyl alcohol)
2. Draw up desired volume into sterile syringe
3. Inject into MT-II vial at angle (avoid excessive pressure)
4. Let sit 2–3 minutes; gently swirl (do not shake vigorously)
5. Draw solution into insulin syringe; solution should be clear

Injection Technique

1. Swab injection site (abdomen, thigh, or deltoid) with alcohol prep pad
2. Pinch skin fold gently; insert needle at 45° angle into subcutaneous layer
3. Inject slowly over 5 seconds (rapid injection increases nausea risk)
4. Withdraw needle; apply light pressure with gauze
5. Rotate injection sites to prevent lipohypertrophy

Optimal Sites: Lower abdomen, outer thigh, or upper deltoid. Avoid the same spot consecutively.

Storage Requirements

• Powder (unopened): Room temperature, cool/dry location; stable 24+ months
• Reconstituted solution (refrigerated): 2–4 weeks at 2–8°C
• Reconstituted solution (room temperature): 1–2 weeks
• Opened powder vials: Discard after 30 days if not reconstituted
• Do not freeze; do not expose to direct sunlight

Cycle Example: 12-Week Complete Tanning & Energy Cycle

Nausea management: If severe during loading, reduce to 0.1–0.2 mg and extend loading phase to 3 weeks.

What to Expect: Timeline of Effects

Hours 0–1

• Injection site warmth and mild erythema
• Facial flushing (transient, resolves in 15–30 minutes)
• Subtle nausea onset (peaks at 30–60 minutes post-injection)

Hours 1–4

• Appetite suppression begins (stronger at higher doses)
• Possible yawning and mild fatigue
• Sexual arousal/spontaneous erections (especially at 0.3+ mg doses)

Days 2–5

• Visible tan darkening, particularly on sun-exposed areas
• Moles and freckles darken noticeably
• Appetite remains suppressed; food aversion possible
• Fatigue subsides with continued dosing

Weeks 2–4

• Plateau in pigmentation (baseline tan is "locked in")
• Appetite suppression plateaus; some tolerance develops
• Sexual function effects stabilize
• Systemic side effects (flushing, nausea) typically resolve

Weeks 4–8

• Tan deepens further with sun exposure and continued dosing
• Appetite suppression persists but becomes less pronounced
• Minimal acute side effects reported

Weeks 8–12

• Pigmentation very stable; dosing frequency can be reduced significantly
• Appetite suppression may require tolerance breaks
• Energy expenditure effects plateau

Signs It's Working & When to Adjust

Skin Tanning (Primary Indicator)

• Day 3–4: Subtle darkening of existing freckles and moles
• Day 7–10: Visible tan across face and forearms without sun exposure
• Week 2: Full-body pigmentation apparent; tan extends to normally unexposed areas
• Adjustment: If tan is slow, increase daily dose by 0.1 mg or shift to daily during loading

Appetite Suppression (Secondary Indicator)

• Day 1–2: Subtle reduction in appetite; meals feel more satiating
• Day 3–5: Pronounced appetite suppression; meals feel less rewarding
• Week 2: Appetite suppression may be too aggressive; reduce frequency if not eating enough
• Adjustment: If minimal appetite loss, increase dose by 0.1 mg or confirm reconstitution quality

Sexual Function (Tertiary Indicator)

• First dose: Possible spontaneous erection within 20–45 minutes (even without sexual stimulus)
• Subsequent doses: Erections predictable with sexual stimulation; increased libido noticeable
• Week 2: Sexual desire enhancement becomes baseline
• Adjustment: If erections are insufficient, increase dose by 0.05–0.1 mg; if too aggressive (priapism risk), reduce by 0.05 mg

When NOT Seeing Effects by Week 2:

• Verify reconstitution: MT-II may be degraded if stored improperly
• Confirm injection depth is truly subcutaneous (not intradermal or intramuscular)
• Increase daily dose by 0.1–0.2 mg if tolerance is suspected
• Consider nasal route if injection yields no response (suggests absorption failure)

Common Protocol Mistakes

1. Injecting too rapidly: Causes severe nausea. Inject over 5+ seconds into subcutaneous tissue.

2. Reconstituting with non-sterile water: Risk of infection and inactivation. Use only bacteriostatic water.

3. Not rotating injection sites: Leads to lipohypertrophy and reduced absorption. Use 4–6 sites in rotation.

4. Excessive loading dose: Doses >0.5 mg daily increase priapism and systemic toxicity risk without faster tanning.

5. Skipping dermatological screening: Dysplastic nevi and melanoma risk is unresolved. Baseline exam is mandatory.

6. Not tapering before breaks: Abrupt cessation after high-dose cycles can trigger rebound effects (hunger, fatigue). Always taper over 1–2 weeks.

7. Combining with high-dose UV exposure: MT-II + sunbed use increases melanoma risk substantially. Avoid sunbeds entirely; limit outdoor sun to 20–30 minutes daily.

8. Ignoring priapism symptoms: Erections >4 hours require immediate ED care. Prolonged priapism causes permanent erectile dysfunction.

9. Using the same vial >4 weeks: Reconstituted MT-II degrades; efficacy drops, side effects may increase.

10. Stacking without research: MT-II + sympathomimetics (ephedrine, caffeine at high doses) increase cardiovascular stress. Avoid concurrent use.

How to Stack with Other Compounds

Low-Risk Stacks (Metabolic Support)

MT-II + GLP-1 Agonist Analogs (e.g., semaglutide, tirzepatide)

• Synergistic appetite suppression and fat loss
• Dosing: Standard MT-II protocol (0.25–0.5 mg 2–3× weekly) + GLP-1 at manufacturer dose
• Timing: Inject MT-II 2–4 hours before GLP-1 to avoid nausea stacking
• Caution: Monitor blood glucose; combination may increase hypoglycemia risk in lean individuals
• Duration: 12–16 week cycle with 6–8 week break

MT-II + Thyroid Hormone (T3, T4)

• Increases central energy expenditure
• Dosing: MT-II 0.25 mg 3× weekly + T3 starting 25 µg daily (or T4 75–100 µg daily)
• Timing: Both dosed morning; separate by 4 hours for absorption
• Caution: Thyroid monitoring required; avoid if existing thyroid dysfunction
• Duration: 12 week maximum; include 4–week washout

MT-II + Metformin (Insulin Sensitizer)

• Supports glucose disposal and lean mass preservation
• Dosing: MT-II 0.25 mg 3× weekly + metformin 1000–1500 mg daily (split dose)
• Timing: Separate by 2 hours; metformin taken with food
• Caution: GI upset may be additive; begin metformin at 500 mg daily and titrate
• Duration: 16 week cycle

Medium-Risk Stacks (Sympathomimetic Caution)

MT-II + Caffeine/Theophylline (Energy Amplification)

• Additive effects on CNS stimulation and energy expenditure
• Dosing: MT-II 0.25 mg 3× weekly + caffeine max 200 mg daily (or theophylline 100 mg 2× daily)
• Timing: Stagger injections >6 hours from caffeine dose to prevent acute sympathetic surge
• Caution: Increased heart rate, blood pressure, and palpitation risk
• Monitoring: Resting heart rate and blood pressure weekly; discontinue if resting HR >90 or BP >140/90
• Duration: 12 week maximum; include 4–week washout

High-Risk Stacks (Avoid)

• MT-II + Ephedrine: Excessive sympathomimetic stimulation; risk of rhabdomyolysis, hypertensive crisis, arrhythmia
• MT-II + High-Dose Androgens (testosterone >500 mg/week, trenbolone): Both increase aggression, sexual arousal, and priapism risk; cardiovascular stress additive
• MT-II + Stimulant Drugs (amphetamine, methamphetamine, cocaine): Dangerous sympathomimetic stacking; risk of sudden cardiac death

Protocol Quick Reference Table

Final Considerations

Melanoma Risk & Dermatological Monitoring

MT-II's mechanism—activation of melanocortin receptors on melanocytes—inherently stimulates pigment production. Case reports document:

• Dysplastic nevi erupting within one week of injection
• Melanoma diagnosis following 3–4 weeks of use combined with UV exposure
• Rapid mole proliferation during loading phases

Mandatory precautions:

• Full-body skin exam and baseline